Hanmi to reinforce injectable anticancer drug lines.
Published: 2006-04-11 06:57:00
Updated: 2006-04-11 06:57:00
Hanmi announced recently to launch 2 injectable anti-cancer drugs such as Gembin (Gemcitabine) for the indication of non-small cell lung, bladder and pancreatic cancers and Inotecan (Irinotecan) in April and Liplatin (Oxaliplatin)
Gemcitabine bulk production was patented by Hanmi, first in Ko...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
